

# Tamara Darsow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5578455/publications.pdf>

Version: 2024-02-01

19  
papers

1,961  
citations

516681

16  
h-index

794568

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

4652  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. <i>Diabetes</i> , 2017, 66, 241-255.	0.6	454
2	A Multispecificity Syntaxin Homologue, Vam3p, Essential for Autophagic and Biosynthetic Protein Transport to the Vacuole. <i>Journal of Cell Biology</i> , 1997, 138, 517-529.	5.2	332
3	Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. <i>Clinical Therapeutics</i> , 2012, 34, 1247-1258.e22.	2.5	229
4	Vam7p, a SNAP-25-Like Molecule, and Vam3p, a Syntaxin Homolog, Function Together in Yeast Vacuolar Protein Trafficking. <i>Molecular and Cellular Biology</i> , 1998, 18, 5308-5319.	2.3	187
5	Acidic Di-leucine Motif Essential for AP-3-dependent Sorting and Restriction of the Functional Specificity of the Vam3p Vacuolar t-SNARE. <i>Journal of Cell Biology</i> , 1998, 142, 913-922.	5.2	130
6	Formation of AP-3 transport intermediates requires Vps41 function. <i>Nature Cell Biology</i> , 1999, 1, 346-353.	10.3	122
7	Cytoplasm to vacuole trafficking of aminopeptidase I requires a t-SNARE-Sec1p complex composed of Tlg2p and Vps45p. <i>EMBO Journal</i> , 1999, 18, 6005-6016.	7.8	113
8	Vps41p Function in the Alkaline Phosphatase Pathway Requires Homo-oligomerization and Interaction with AP-3 through Two Distinct Domains. <i>Molecular Biology of the Cell</i> , 2001, 12, 37-51.	2.1	80
9	Exocytic Trafficking Is Required for Nicotine-induced Up-regulation of $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptors. <i>Journal of Biological Chemistry</i> , 2005, 280, 18311-18320.	3.4	65
10	Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. <i>Vascular Health and Risk Management</i> , 2006, 2, 203-212.	2.3	43
11	Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research Symposium. <i>Diabetes</i> , 2015, 64, 2299-2309.	0.6	41
12	Incretin-based therapies. <i>Journal of Diabetes</i> , 2012, 4, 55-67.	1.8	39
13	Pramlintide as An Adjunct to Insulin in Patients with Type 2 Diabetes in A Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, And Weight. <i>Diabetes Technology and Therapeutics</i> , 2007, 9, 191-199.	4.4	35
14	Invertase fusion proteins for analysis of protein trafficking in yeast. <i>Methods in Enzymology</i> , 2000, 327, 95-106.	1.0	30
15	The American Diabetes Association Diabetes Research Perspective. <i>Diabetes Care</i> , 2012, 35, 1380-1387.	8.6	21
16	Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2008, 24, 103-108.	4.0	17
17	The American Diabetes Association Diabetes Research Perspective. <i>Diabetes</i> , 2012, 61, 1338-1345.	0.6	14
18	Is the metabolic syndrome a real clinical entity and should it receive drug treatment?. <i>Current Diabetes Reports</i> , 2006, 6, 357-364.	4.2	7

#	ARTICLE	IF	CITATIONS
19	Pramlintide as an Adjunct to Basal Insulin: Effects on Glycemic Control and Weight in Patients with Type 2 Diabetes Mellitus. <i>Insulin</i> , 2007, 2, 166-172.	0.2	2